Axsome Therapeutics, Inc. (AXSM) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

14/25

Growth 4 Margin 4 Expansion 3 Platform 0 Financial 3

latest quarter score

Earnings Reports

14
Axiom Therapeutics (AXSM) Q2 2026: 46% Revenue Growth Driven by Alzheimer's Agitation Launch and Neuroscience Pipeline Progress
August 10, 2026
12
Axsome Therapeutics (AXSM) Q1 2026: Ovelity Peak Sales Raised to $8B on Alzheimer’s Agitation Expansion
May 04, 2026
13
Axsome Therapeutics (AXSM) Q4 2025: Avelity Scripts Jump 42% as Commercial Platform Scales
February 24, 2026
14
Axsome (AXSM) Q3 2025: 63% Revenue Surge Anchors Pipeline-Driven Growth Trajectory
November 03, 2025
14
Axsome (AXSM) Q2 2025: Avelity Scripts Jump 15% as Coverage Expansion Drives Prescriber Uptake
August 04, 2025
17
Jazz Pharmaceuticals (JAZZ) Q1 2025: Chimerix Deal Adds $890M R&D Charge, Oncology Pipeline Readout Looms
July 06, 2025
Axsome Therapeutics (AXSM) Q3 2024: Avelity Prescriptions Surge 108% as Pipeline Readouts Near
November 12, 2024
Axsome Therapeutics (AXSM) Q2 2024: Avelity Prescriptions Surge 131% as Payer Access Expands by 22M Lives
August 05, 2024
Axsome Therapeutics (AXSM) Q1 2024: Avelity Prescriptions Jump 206% as Coverage Expands, Pipeline Milestones Stack Up
May 06, 2024
8
Axsome Therapeutics (AXSM) Q4 2023: Commercial Revenue Triples, Pipeline Execution Sets Up 5 Late-Stage Readouts
January 04, 2024
9
Axsome Therapeutics (AXSM) Q3 2023: Prescription Growth Hits 30% as Avelity Expansion Targets 44,000 Prescribers
November 06, 2023
Axsome Therapeutics (AXSM) Q2 2023: Field Force Expands 60%, Targeting 44,000 Prescribers for Avelity
August 07, 2023
Axsome Therapeutics (AXSM) Q1 2023: Availity Prescriptions Surge 298%, Fueling Commercial Ramp
May 08, 2023
Axsome Therapeutics (AXSM) Q4 2022: Dual Launch Drives $24M Sales, Pipeline Milestones Accelerate
February 27, 2023

Browse all companies